HLB resubmits FDA application for liver cancer treatment

HLB, a Korean drugmaker, has resubmitted its application to the US Food and Drug Administration (FDA) for approval of a new treatment for advanced liver cancer. This combination therapy, which pairs rivoceranib with camrelizumab, aims to become a first-line treatment for liver cancer patients. The resubmission addresses regulatory concerns raised earlier this year, and if approved, it could bring a new option to patients with this serious disease. The outcome of this application will be closely watched by investors in the biopharmaceutical sector.

Why it matters

HLB has resubmitted its application for U. S.

Market impact

Markets & countries in focus

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to The Korea Times. For information only — not financial advice.